Topic summary

What a regulator's shortage notice actually authorises — what changed since

Sourcing › Regulatory research use only EMA FDA compounding MHRA Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 27, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

j.marchettiTL2 Moderator27 Jul 2025#1

The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it.

A logistics question, since the answers here are usually better than anywhere else I have looked.

Parcel despatched 7 days ago, tracking last updated 3 days ago at a customs facility, no further movement. Cold pack included at despatch.

Two questions. First, at what point is this genuinely a problem rather than an ordinary delay? Second, if it does arrive, what is the actual decision process for assessing it, as opposed to the two extremes people usually offer?

57 likes 12mo

r.vukovicTL2 Moderator Solution24 Aug 2025#4

post #2 answers the question as asked. The question underneath it is different.

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

8 likes 11mo

z.okonkwoTL2 Moderator2 Oct 2025#10

Picking up post #7: that is the part I would want checked first.

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

30 likes 10mo

i.amankwahTL2 Moderator14 Nov 2025#18

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

28 likes 8mo

j.sandvikTL2 Moderator22 Dec 2025#26

This follows post #23 rather than contradicting it.

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

25 likes 7mo

Read the full topic (27 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: How compounding permissions changed when supply normalised Sourcing › Regulatory MHRA personal import research use only How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion, following the…	+72	77	1.5k	1d
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…		2	62k	15mo
Research-use-only labelling: what it means and what it does not Sourcing › Regulatory compounding research use only EMA FDA Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. I would like to talk about documentation quality as a…	+100	110	37k	5mo
How compounding permissions changed when supply normalised Sourcing › Regulatory personal import EMA compounding research use only Solved Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised Structured report rather than an opinion, following the format the maintainers asked…	+30	34	51k	16mo
Pharmaceutical compounding rules, summarised from primary sources Sourcing › Regulatory MHRA EMA research use only Closed Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…	+135	163	46k	17mo

Related topics — sharing the tags research use only, EMA, FDA

Topic	Participants	Replies	Views	Activity
Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds needs a source mislabelling research use only custom synthesis Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…	+7	11	5.5k	20mo
Currency conversion and the cost you did not see Sourcing › Payments payments research use only documentation quality Currency conversion and the cost you did not see — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the maintainers asked for.…		2	44k	2mo
Sequence verification for an obscure compound: how it is done Compounds › Other compounds needs a source custom synthesis research use only mislabelling Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with SURMOUNT-1 ( N…	+104	114	10k	12mo
Prescription requirements and telehealth models Sourcing › Regulatory FDA compounding research use only MHRA Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are usually better than anywhere…	+91	97	5.4k	7mo
Coverage in the US: a map of the usual obstacles Regional › North America FDA insurance telehealth compounding Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…	+46	50	7.9k	5mo